Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines

Oncology Reports

Volumn 14, Issue 3, 2005, Pages 645-650

  Noma, Kazuhiro ^a   Naomoto, Yoshio ^a   Gunduz, Mehmet ^a   Matsuoka, Junji ^a   Yamatsuji, Tomoki ^a   Shirakawa, Yasuhiro ^a   Nobuhisa, Tetsuji ^a   Okawa, Takaomi ^a   Takaoka, Munenori ^a   Tomono, Yasuko ^b   Hiroyuki, Ohmori ^b   Gunduz, Esra ^a   Tanaka, Noriaki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Shigei Medical Research Institute   (Japan)

Author keywords

Gastrointestinal tumor; KIT mutation

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; IMATINIB; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; GASTROINTESTINAL STROMAL TUMOR; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; TIME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MUTATION; PHOSPHORYLATION; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TIME FACTORS;

EID: 24644492934     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.3.645     Document Type: Article

References (29)

1. Fishman AP: Gastrointestinal tract. In: Ackerman's Surgical Pathology (8th edition), Rosai J (Ed), St. Louis, Mosby, pp645-647, 1996.
2. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio G M, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580, 1998. (Pubitemid 28067289)
3. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM: Gastrointestinal stromal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152: 1259-1269, 1998. (Pubitemid 28221878)
4. Sircar K, Hewlett BR, Huizinga JD, Chrneyko K, Berezin I, Riddell RH: Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 23: 377-389, 1999. (Pubitemid 29159998)
5. Thomsen L, Robinson TL, Lee JCF, Farraway LA, Hughes MJG, Andrews DW, Huizinga JD: Interstitial cells of Cajal generate a rhythmic pacemaker current. Nat Med 4: 848-851, 1998. (Pubitemid 28331030)
6. Yarden Y, Kuang WJ, Yang-Feng T, Coussecs L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A: Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6: 3341-3351, 1987.
7. Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CDM, Fletcher JA: KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156: 791-795, 2000. (Pubitemid 30626936)
8. Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T, Kitamura Y: Gain-of -function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 193: 505-510, 2001. (Pubitemid 32266820)
9. Mauro MJ, Druker BJ: STI571: targeting BCR-ABL as therapy for CML. Oncologist 6: 233-238, 2001. (Pubitemid 32592214)
10. Bruchdunger E, Zimmermann J, Meu H, Meyer T, Muller M, Druker BJ, Lydon NB: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100-104, 1996.
11. Okuda K, Weisberg E, Gilliland G, Griffin JD: ARG tyrosine kinase activity is inhibited by STI571. Blood 97: 2440-2448, 2001. (Pubitemid 32291492)
12. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-KIT and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139-145, 2000.
13. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ: Inhibition of c-KIT receptor tyrosine activity by STI571, a selective tyrosine kinase inhibitor. Blood 96: 925-932, 2000. (Pubitemid 30618049)
14. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037, 2001. (Pubitemid 32267972)
15. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038-1042, 2001. (Pubitemid 32267973)
16. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS: Safety and efficacy of imatinib(ST1571) in metastatic gastrointestinal stromal tumours: a phase 1 study. Lancet 358: 1421-1423, 2001. (Pubitemid 33055745)
17. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G: Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3: 655-664, 2002. (Pubitemid 35314908)
18. Heinrich MC, Blanke CD, Druker BJ, Corless CL: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20: 1692-1703, 2002. (Pubitemid 34260552)
19. Heinrich MC, Corless CL, Blanke C, Demetri GD, Joensuu H, Van Mehren M, McGreevey LS, Wait CL, Griffith D, Chen C-J, Haley A, Kicse B, Druker B, Roberts P, Eisenberg B, Singer S, Silberman S, Dimitrijevic S, Fletcher CD, Fletcher JA: KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Prog Proc Am Soc Clin Oncol 21: 2a, 2002.
20. Chen H, Isozaki K, Kinoshita K, Ohashi A, Shinomura Y, Matsuzawa Y, Kitamura Y, Hirota S: Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. Int J Cancer 105: 130-135, 2003. (Pubitemid 36418498)
21. Casteran N, De Sepulveda P, Beslu N, Aoubala M, Letard S, Lecocq E, Rottapel R, Dubreuil P: Signal transduction by several KIT juxtamembrane domain mutations. Oncogene 22: 4710-4722, 2003. (Pubitemid 36976446)
22. Tsujimura T, Morimoto M, Hashimoto K, Moriyama Y, Kitayama H, Matsuzawa Y, Kitamura Y, Kanakura Y: Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Blood 87: 273-283, 1996. (Pubitemid 26011841)
23. Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H, Sugahara H, Mitsui H, Kanayama Y, Kitamura Y, Matsuzawa Y: Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 85: 790-798, 1995.
24. Frolov A, Chahwan S, Ochs M, Arnoletti JP, Pan ZZ, Favorova O, Fletcher J, von Mehren M, Eisenberg B, Godwin AK: Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther 2: 699-709, 2003.
25. Paner GP, Silberman S, Hartman G, Micetich KC, Aranha GV, Alkan S: Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors. Anticancer Res 23: 2253-2260, 2003. (Pubitemid 36897088)
26. Amborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali PG, Pierotti MA, Pilotti S: A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127: 294-299, 2004. (Pubitemid 38962296)
27. Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, Gonen M, Segal NH, Maki RG, Socci ND, DeMatteo RP, Besmer P: Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 10: 3282-3290, 2004. (Pubitemid 38685432)
28. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML: A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64: 5913-5919, 2004. (Pubitemid 39129383)
29. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, Fletcher CD, Demetri GD, Fletcher JA: Mechanismas of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23: 3999-4006, 2004. (Pubitemid 38747928)